HCMSG The Hepatitis C Mentor & Support Group, Inc.
Search
  • Home
  • About Us
    • Our Mission
    • Board of Directors
  • Resources
    • Hep C Facts & Stats
    • Patient Assistance Programs
    • Research and Publications
    • Reading
    • Links
    • UpcomingEvents
  • Programs/Training
    • The Hepatitis C Education and Support Group Assistance Program
    • The Circle >
      • THE CIRCLE Registration
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
    • Holiday 2018
  • Contact Us

A Time to Cure: The Growing Case for New Hepatitis C Treatments

8/15/2015

1 Comment

 
Ryan Clary -Executive director of the National Viral Hepatitis Roundtable

One out of every 100 Americans is living with a deadly and communicable virus, yet most can't access the cure which will save their lives and halt the disease's lethal trajectory.

Hepatitis C now kills more Americans each year than HIV/AIDS and is 10 times more infectious. It has become a leading cause of liver failure and liver cancer -- the fastest-rising cause of all cancer-related deaths. For too long this blood-borne virus has silently ravaged communities across the country, often going unnoticed and untreated until it was too late. Until 2013, the only treatments for hepatitis C were painful and effective only half the time, leaving many patients with nowhere to turn, despite their diagnosis.

But now the tide is turning. Multiple treatments for hepatitis C currently offer cure rates of near 100 percent with minimal side effects. Now some of the biggest obstacles facing hepatitis C patients are health insurers.

Many private health plans and most Medicaid programs are requiring patients to first reach late-stage, often irreversible, liver disease before they can access effective treatment, and some are even denying access to many people with a history of substance abuse and to people living with HIV.

According to new research led by the Center for Health Law and Policy at Harvard Law School, 42 state Medicaid programs with stringent restrictions for hepatitis C treatment may even be violating federal Medicaid law, which requires states to cover drugs consistent with their FDA labels.

Access for privately insured Americans is similarly dismal, with many health plans imposing comparable restrictions and then requiring exorbitant copays that place a cure squarely out of reach for most patients.

A growing body of research is also proving that these restrictions will have costly ramifications for both patient health and the U.S. health care system, especially as the baby boomer population--which is most at-risk for hepatitis C--reaches Medicare eligibility.

A new Milliman study finds that connecting baby boomers with a cure would save 53,000 lives over the next decade and save taxpayers $4.5 billion as this demographic transitions to Medicare. It's also worth noting that the true impact of such treatment access is likely even bigger because while the study considered patients who are currently aware of their infection, a growing number of baby boomers are diagnosed each day.

Recent research also suggests that curing hepatitis C can yield cost savings for private insurers and Medicaid in the short-term by reducing the need for hospitalization, liver transplants and other costly procedures. A study funded by the National Institutes of Health finds that innovative treatments are cost effective in 83 percent of new patients and 81 percent of previously treated patients. And additional research published in Clinical Infectious Diseases suggests that immediately treating hepatitis C patients with new treatments is cost effective, even for those with only moderate disease progression.

By imposing discriminatory treatment restrictions, Medicaid and private insurers are not only putting the lives of millions of Americans at risk; they are also fanning the flames of a major public health threat while driving up long-term health care costs for themselves and for American taxpayers.

The reality is that hepatitis C is the only deadly disease for which curative treatment is widely withheld from patients. Imagine if an insurer mandated that a cancer patient reach metastatic levels before receiving chemotherapy, or that a diabetic lose a limb before being eligible for insulin treatment.

It's time to end this blatant unethical and short-sighted disease discrimination. It's time to cure hepatitis C.

Ryan Clary is the executive director of the National Viral Hepatitis Roundtable (NVHR), a coalition working to fight, and ultimately end, the hepatitis B and C epidemics in the United States.


http://m.huffpost.com/us/entry/7976444?1439501385

MORE:HepatitisLiverLiver Disease
1 Comment
Karl Wilson
10/7/2015 07:44:25 am

HOW I GOT CURED FROM HEPATITIS B VIRUS)
I am from Malasia, I was diagnosed of Hepatitis B Virus
(HBV) in 2009 and I have tried all I can to get cured but all to no avail, until i saw a post in a
health forum about a herbalist who prepare herbal cure to cure all kind of diseases including Hepatitis
B virus, at first i doubted if it was real but decided to give
it a try, when i contact this herbalist via his email, he prepared an HBV herbal cure and sent it to
me via courier service, when i received this herbal cure, he gave me step by directions on
how to apply it, when i applied it as instructed, i was cured of this deadly disease within
3 days, I am now free from the deadly disease, all thanks to Dr OYEKPEN. Contact this great
herbal spell caster via his email: droyekpenherbalhome@hotmail.com or call him on his phone +2348168257144,
he also told me that he have cure for any kind of disease like:
HIV
CANCER
HERPES
AUTISM
DIABETES
E.T.C.

Thanks you one once again.

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy